The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index.
The role of androgens and the androgen receptor in prostate cancer.
Abstract
Prostate cancer (PCa) is the leading diagnosed malignancy in men in western countries. The relationship between androgens and the androgen receptor (AR) has been studied extensively in PCa. Plasma levels of androgens show variations between different populations, and in many cases this correlates with PCa susceptibility. Indeed, exposure of the fetus to higher androgen concentrations appears to be a risk factor for PCa. The AR is present in the majority of PCa, and its activation by androgens leads to different proliferative, apoptotic and angiogenic events. These events are in turn mediated by dysregulation of cyclin-dependent kinases, apoptotic factors and even mutations in the AR. Although androgen ablation has been the mainstay non-surgical treatment for this disease, most tumors will eventually become refractory to treatment. Different cellular mechanisms appear to be involved in the androgen-independent progression of PCa, including cytokine and growth factor-mediated activation of the AR as well as neuroendocrine differentiation. Thus, an understanding of the cellular mechanisms involved in androgen action may lead to better therapeutic targets for PCa.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite CR tumor cells being able to continue to grow after hormonal therapy in which testosterone and dihydrotestosterone are markedly reduced, they still require the expression and activity of the AR.”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [5]
In the citing paper
“It is now a central tenet that the expression and activity of the AR is still required for survival and growth of many types of CR prostate cancers”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [5]
Citations
Cites
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Walsh, M. P. C. (1986) · Cited by 3,466
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E. L., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,992
Huggins, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,694
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,243
Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,149
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 594
Research works printed but not linked: 1
- Debes, 2002, Proc. AACR, 43
Cited by
Sorted by citations
Protective effect of green tea against prostate cancer: A case‐control study in southeast China
Jian, L., Xie, L., Lee, A. H., & Binns, C. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11550 · Cited by 369
Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N. M., & Abrahamsson, P. (2004) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
p300 in prostate cancer proliferation and progression.
Debes, J. D., Sebo, T. J., Lohse, C. M., Murphy, L. M., Haugen, D. A. L., & Tindall, D. J. (2003) · PubMed · Cited by 219
Self-citationWu, C., Altuwaijri, S., Ricke, W. A., Huang, S., Yeh, S., Zhang, C., Niu, Y., Tsai, M.-Y., & Chang, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704940104 · Cited by 211
Bakin, R. E., Gioeli, D. G., Sikes, R. A., Bissonette, E. A., & Weber, M. J. (2003) · PubMed · Cited by 201
Metadata
- Authors
- Debes, J. D., & Tindall, D. J.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Tindall, Donald J
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 187
- Issue
- 1-2
- Pages
- 1-7
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2141562227
- Cited by
- 191
- References
- 77
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 8 · 2012: 10
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 91956, P50CA091956)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK60920, R01DK060920)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, androgens, androgen receptor, androgen receptor mutations, androgen-independent progression, androgen deprivation therapy, neuroendocrine differentiation, cyclin-dependent kinases, apoptosis, angiogenesis, prenatal androgen exposure, therapeutic target
- MeSH terms
- Androgens, Humans, Male, Neoplasms, Hormone-Dependent, Prostate, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
